Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells – Nasdaq
|
Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR–T cells
Nasdaq This new patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR–T cells per se, and to methods of producing them. |
